JAX investigators in the lab of Derya Unutmaz recently submitted an article for publication about a new assay that determines how well anti-SARS-CoV-2 antibodies are able to neutralize binding with ACE-2, the human receptor for the virus. The article is now available as a preprint on medRxiv.
Mark Wanner has also released a Research Highlight article on the Jackson Laboratory website, where he explains the study in detail and speculates on what the findings could mean in terms of determining disease susceptibility and progression in patients. This new assay may help aid in understanding the quality or duration of the antibody response during COVID-19, and have important implications in public health and vaccine effectiveness.
To read the Research Highlight by Mark Wanner, click here.
